Challenge (Importazione parallela)

Informazioni principali

  • Nome commerciale:
  • Challenge (Importazione parallela)
  • Forma farmaceutica:
  • SC sospensione concentrata
  • Utilizzare per:
  • Piante
  • Tipo di medicina:
  • Agrochimico

Documenti

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • Challenge (Importazione parallela)
    Svizzera
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • Erbicida

Altre informazioni

Status

  • Fonte:
  • UFAG - Ufficio federale dell'agricoltura. OFAG - Office fédéral de l'agriculture. BLW - Bundesamt für Landwirtschaft.
  • Numero dell'autorizzazione:
  • I-3232
  • Ultimo aggiornamento:
  • 18-11-2018

Foglio illustrativo: composizione, posologia, indicazioni, interazioni, gravidanza, allattamento, effetti indesiderati, controindicazioni

Denominazione commerciale: Challenge

(Importazione parallela)

Elenco dei prodotti fitosanitari (stato: 06.11.2018)

Categoria di prodotti:

Titolare dell'autorizzazione

all'estero:

Numero federale di omologazione:

Erbicida

Bayer S.p.A.

I-3232

Principio:

Tenore:

Codice di formulazione:

Principio attivo: Aclonifen 49.6 % 600 g/l

SC sospensione concentrata

Applicazioni

A

Coltura

Agente patogeno/

Efficacia

Dosaggio

Restrizioni

Aglio

Cipolle

[trapiantato]

Scalogni

[trapiantato]

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 3 l/ha

Applicazione: In pre-emergenza.

1, 4, 5, 6, 8

Aglio

Cipolle da

tavola

[seminato]

Cipolle dolci

[seminato]

Scalogni

[seminato]

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 1.33 l/ha

Applicazione: Trattamento frazionato: 1°

trattamento con 0.33 l/ha tra lo stadio orecchiette

di topo avanzato e quello di 2 foglie (BBCH 10-

12), 2° trattamento con 0.33-0.5 l/ha (BBCH 12-

13), 3° trattamento con 0.5 l/ha (BBCH 14).

2, 3, 4, 6, 7,

8, 9

Pieno campo:

Aneto

Pieno campo:

Carvi

Pieno campo:

Finocchio

aromatico

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2.5 l/ha

Applicazione: L'anno della semina. In pre-

emergenza.

4, 5, 6, 10,

12, 13, 14

G Pieno campo:

Aneto

Pieno campo:

Carvi

Pieno campo:

Finocchio

aromatico

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2.5 l/ha

Applicazione: L'anno della semina. In pre-

emergenza.

4, 5, 6, 10,

11, 13

A

Coltura

Agente patogeno/

Efficacia

Dosaggio

Restrizioni

Pieno campo:

Prezzemolo

G Carote

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2 - 2.5 l/ha

Termine d'attesa: 70 Giorni

Applicazione: Trattamento frazionato: 1 - 1.5 l/ha

in pre-emergenza (immediatamente dopo la

semina) più 1.0 l/ha in post-emergenza (BBCH

13).

3, 4, 6, 8

G Carote

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 3 l/ha

Termine d'attesa: 80 Giorni

Applicazione: In pre-emergenza.

4, 5, 6, 8

Pieno campo:

Carvi

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2.5 l/ha

Applicazione: Primavera. Stadio 13-39 (BBCH).

4, 5, 6, 10,

12, 13, 14

Pieno campo:

Coriandolo

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2.5 l/ha

Applicazione: Dopo la semina, in pre-emergenza.

4, 5, 6, 10,

12, 13, 14

Finocchio dolce

[seminato]

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2 l/ha

Termine d'attesa: 90 Giorni

Applicazione: In pre-emergenza fino a 2 giorni

dopo la semina.

3, 4, 6, 15

Finocchio dolce

[piantato]

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2 l/ha

Termine d'attesa: 70 Giorni

Applicazione: Immediatamente prima della

piantagione.

3, 4, 6, 15

G Lenticchia

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 3 l/ha

Applicazione: Trattamento frazionato: 2.0 l/ha in

pre-emergenza più 1.0 l/ha o 2 x 0.5 l/ha in post-

emergenza (dallo stadio 3 foglie allo stadio 9

foglie della coltura).

3, 4, 6, 8, 13

G Lenticchia

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 3 l/ha

Applicazione: In pre-emergenza.

4, 5, 6, 8, 13

Pieno campo:

Pastinaca

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2.5 l/ha

Termine d'attesa: 90 Giorni

Applicazione: In pre-emergenza.

4, 5, 6, 10, 13

A

Coltura

Agente patogeno/

Efficacia

Dosaggio

Restrizioni

G Piselli

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 1 l/ha

Applicazione: In post-emergenza.

3, 4, 6

G Piselli

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2 l/ha

Applicazione: In pre-emergenza.

3, 4, 6

G Sedano

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2 l/ha

Termine d'attesa: 90 Giorni

Applicazione: Dopo la radicazione della coltura.

ca. 7 giorni dopo la piantagione.

3, 4, 6, 13, 15

G Topinambur

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2.5 l/ha

Termine d'attesa: 90 Giorni

Applicazione: In pre-emergenza. stadi 00-08

(BBCH).

4, 5, 6, 10, 13

Fava

Girasole

Patate

Pisello proteico

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2.25 - 3 l/ha

Applicazione: In pre-emergenza.

2, 5, 6

Fava

Girasole

Pisello proteico

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 2 l/ha

Applicazione: In pre-emergenza.

3, 6, 16

F Lupini

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 1 - 2 l/ha

Applicazione: stadi 00-07 (BBCH).

3, 6, 10, 13

F Patate

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 1.5 - 2 l/ha

Applicazione: In pre-emergenza.

3, 6, 16

F Pisello proteico

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 1 l/ha

Applicazione: In post-emergenza.

3, 6

F Sorgo

Dicotiledoni

annuali (malerbe)

Monocotiledoni

annuali (malerbe).

Dose: 1.5 l/ha

Applicazione: stadi 00-07 (BBCH).

3, 6, 10, 13

Restrizioni e osservazioni:

Non applicare su suoli sabbiosi.

Bassa dose d'applicazione utilizzabile unicamente in una miscela estemporanea secondo le

indicazioni del titolare dell'autorizzazione.

SPe 3: Per proteggere organismi acquatici dagli effetti della deriva rispettare una zona tampone

non trattata di 20 metri dalle acque superficiali. Per la protezione contro gli effetti di un

dilavamento, rispettare una zona tampone con copertura vegetale a una distanza di almeno 6 metri.

Riduzione della distanza a causa di deriva ed eccezioni secondo le istruzioni dell'UFAG.

Lavori successivi in colture trattate: indossare guanti + indumenti protettivi fino a 48 ore

dall'applicazione del prodotto.

SPe 3: Per proteggere organismi acquatici dagli effetti della deriva rispettare una zona tampone

non trattata di 50 metri dalle acque superficiali. Per la protezione contro gli effetti di un

dilavamento, rispettare una zona tampone con copertura vegetale a una distanza di almeno 6 metri.

Riduzione della distanza a causa di deriva ed eccezioni secondo le istruzioni dell'UFAG.

Durante la preparazione della poltiglia: Indossare guanti di protezione. Applicazione della

poltiglia: Indossare guanti di protezione + indumenti protettivi. I dispositivi di protezione

individuale possono essere sostituiti, durante l'applicazione, da dispositivi di protezione tecnici

(p.es. cabina del trattore chiusa), qualora vi sia la garanzia che offrano una protezione analoga o

superiore.

Trattamenti a intervalli di almeno 7 giorni.

La dose indicata corrisponde al quantitativo totale autorizzato.

Non utilizzare per la produzione di cipollotti a mazzo.

10.Al massimo un 1 trattamento per coltura.

11.Applicazione solamente in colture destinate alla produzione di erbe fresche.

12.Applicazione solamente in colture destinate alla produzione di semi e frutta seccha.

13.Autorizzato come uso minore secondo l'art. 35 OPF (minor use).

14.Applicazione solamente in colture destinate alla produzione di infusi o di condimenti.

15.Occorre far riferimento al rischio di clorosi temporanea della foglia nella fase immediatamente

successiva al trattamento.

16.Utilizzabile unicamente in una miscela estemporanea secondo le indicazioni del titolare

dell'autorizzazione

Caratterizzazione di pericolo:

Si applicano la classificazione e la caratterizzazione dell’etichetta originale estera..

Ulteriori simboli di pericolo svizzeri:

SP 1 Non contaminare l'acqua con il prodotto o il suo imballaggio.

In caso di dubbio valgono soltanto i documenti originali dell'omologazione. La menzione di un prodotto,

principio attivo o di una ditta non rappresenta alcuna raccomandazione.

22-1-2019

Modification of the existing maximum residue levels for aclonifen in celeriacs and certain fresh herbs

Modification of the existing maximum residue levels for aclonifen in celeriacs and certain fresh herbs

Published on: Mon, 21 Jan 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicants Landesanstalt für Landwirtschaft und Gartenbau Sachsen‐Anhalt (LSA) and Dienstleistungszentrum Ländlicher Raum Rheinpfalz (DLR), respectively, submitted a request to the competent national authority in Germany to modify the existing maximum residue levels (MRL) for the active substance aclonifen in chives, parsley, celery leaves/dill leaves, thyme/savoury and in celeriacs/turnip‐rooted celery. The ...

Europe - EFSA - European Food Safety Authority EFSA Journal

8-1-2019

Antimicrobial resistance

Antimicrobial resistance

Antimicrobial resistance is a major international human and animal health issue, because the emergence and spread of drug-resistant strains of bacteria call into question the efficacy of these treatments in humans and animals alike. Preserving the effectiveness of antibiotics is therefore a genuine public health challenge requiring an integrated approach across all types of medicine, according to the "One Health" concept covering both humans and animals. ANSES has mobilised significant resources to addr...

France - Agence Nationale du Médicament Vétérinaire

17-12-2018

 Occupational health: aiming to take better account of multiple exposure

Occupational health: aiming to take better account of multiple exposure

Workers can potentially be exposed to numerous health risk factors through their occupations. The question of multiple exposure is a major challenge for all those active in the field of occupational health, safety and prevention. As part of the 2016-2020 National Occupational Health Plan, a review of the measures taken by the main players to address the question of multiple exposure in France and abroad is being published today. This work has helped determine the state of knowledge and the issues surroun...

France - Agence Nationale du Médicament Vétérinaire

5-12-2018

Public health risks associated with food‐borne parasites

Public health risks associated with food‐borne parasites

Published on: Tue, 04 Dec 2018 Parasites are important food‐borne pathogens. Their complex lifecycles, varied transmission routes, and prolonged periods between infection and symptoms mean that the public health burden and relative importance of different transmission routes are often difficult to assess. Furthermore, there are challenges in detection and diagnostics, and variations in reporting. A Europe‐focused ranking exercise, using multicriteria decision analysis, identified potentially food‐borne ...

Europe - EFSA - European Food Safety Authority Publications

1-12-2018

Safety assessment of the process ‘RecyPET Hungária’, based on RecyPET Hungária technology, used to recycle post‐consumer PET into food contact materials

Safety assessment of the process ‘RecyPET Hungária’, based on RecyPET Hungária technology, used to recycle post‐consumer PET into food contact materials

Published on: Fri, 30 Nov 2018 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP) assessed the safety of the recycling process RecyPET Hungária (EU register number RECYC0146). The input is hot caustic washed and dried poly(ethylene terephthalate) (PET) flakes originating from collected post‐consumer PET containers, containing no more than 5% of PET from non‐food applications. The flakes are dried and extruded. The output of the extrusion step is cut into pellets in an underwater...

Europe - EFSA - European Food Safety Authority Publications

20-11-2018

Vijf winnaars van energieneutrale sportprojecten kunnen aan de slag

Vijf winnaars van energieneutrale sportprojecten kunnen aan de slag

Op 20 november zijn de vijf winnaars van de Innovation Challenge Energieneutrale Sportaccommodaties, vanuit het programma Sportinnovator, bekendgemaakt. De innovatieve ideeën voor energiebesparing bij sportaccommodaties hebben groen licht gekregen. Ze ontvangen hiervoor steun van het ministerie van Volksgezondheid, Welzijn en Sport om innovatie in de sport te bevorderen. Onderstaande initiatieven krijgen 100.000 euro om het idee in de praktijk door te voeren.

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

8-11-2018

Hazard analysis approaches for certain small retail establishments and food donations: second scientific opinion

Hazard analysis approaches for certain small retail establishments and food donations: second scientific opinion

Published on: Wed, 07 Nov 2018 00:00:00 +0100 In 2017, EFSA published a ‘simplified’ food safety management system (FSMS) for certain small retail establishments (butcher, grocer, baker, fish and ice cream shop) based on the application of prerequisite programme (PRP) criteria. The aim of this opinion was to develop similar FSMSs for other small retail enterprises including retail distribution centres, supermarkets, restaurants (including pubs and other catering activities) and food donation. The latter...

Europe - EFSA - European Food Safety Authority Publications

19-9-2018

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

Published on: Tue, 18 Sep 2018 00:00:00 +0200 During the years 2012‐2016, the Dutch National Food Consumption survey was conducted in the Netherlands. For the survey, a random sample was drawn from consumer panels stratified by age and gender and maintained representative to the population with regard to region, address density and educational level. Complete results were obtained for 4,313 persons (response rate 65%); including toddlers, children, adolescents, adults and elderly. Pregnant or lactating ...

Europe - EFSA - European Food Safety Authority Publications

13-9-2018

Use of next‐generation sequencing in microbial risk assessment

Use of next‐generation sequencing in microbial risk assessment

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Despite the ever increase in rigorous control and monitoring measures to assure safe food along the entire farm‐to‐fork chain, the past decade has also witnessed an increase in microbial food alerts. Hence, research on food safety and quality remain of utmost importance. Complementary, and at least as important, is the necessity to be able to assess the potential microbial risks along the food chain. Risk assessment relies on sound scientific data. Unfortuna...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Antimicrobial resistance (AMR) represents a major challenge for Public Health and the scientific community, and requires immediate and drastic solutions. Acquired resistance to certain antimicrobials is already widespread to such an extent that their efficacy in the treatment of certain life‐threatening infections is already compromised. To date, the emergence and spread of AMR has been attributed to the use, misuse or indiscriminate use of antibiotics as th...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Identification and evaluation of potentially mutagenic and carcinogenic food contaminants

Identification and evaluation of potentially mutagenic and carcinogenic food contaminants

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Heat processing of food gives rise to a plethora of chemical compounds whose toxicological effects are largely unknown. Due to a general lack of experimental toxicological data, assessing the risks associated with the consumption of these substances remains a challenge. Computer models that allow for an in silico prediction of physicochemical and toxicological characteristics, may be able to fill current data gaps and facilitate the risk assessment of toxico...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Joint EFSA and ECDC 2018 workshop on preparedness for a multi‐national food safety/public health incident

Joint EFSA and ECDC 2018 workshop on preparedness for a multi‐national food safety/public health incident

Published on: Tue, 21 Aug 2018 00:00:00 +0200 Abstract In May 2018, EFSA and ECDC co‐facilitated a workshop on preparedness for a multi‐national food safety/public health incident. The workshop, hosted at AGES in Vienna, was conceived to closely align with EFSA's Strategy 2020 commitment to prepare for future risk assessment challenges. EFSA, ECDC, AGES and BfR worked together closely to develop a workshop and associated training materials to be delivered over a 2.5‐day agenda. The workshop was attended...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Published on: Fri, 10 Aug 2018 00:00:00 +0200 This scientific opinion of the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) deals with the safety evaluation of the recycling process General Plastic (EU register No RECYC153), which is based on the Starlinger Decon technology. The decontamination efficiency of the process was demonstrated by a challenge test. The input of this process is hot caustic washed and dried poly(ethylene terephthalate) (PET) flakes orig...

Europe - EFSA - European Food Safety Authority Publications

20-8-2018

Danish Medicines Agency lands new European chairmanship

Danish Medicines Agency lands new European chairmanship

Nikolai Brun, Director of Medical Evaluation & Biostatistics, has been elected chair of the Task Force on Big Data in the pharmaceutical area. The task force is a collaboration between the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) which is to identify advantages and challenges of using big data for the development of medicine.

Danish Medicines Agency

20-8-2018

Drug and Alcohol Use During Orientation Week

Drug and Alcohol Use During Orientation Week

OTTAWA – For students entering university and colleges across Canada, orientation week is an exciting time to get to know your new school, classmates and roommates. While parties during orientation week are a great way to celebrate, they can present safety challenges, especially when it comes to the use of alcohol and drugs.

Health Canada

12-7-2018

Carenza Hydrocortisone Roussel - modalità di richiesta d'importazione dall'estero (12/07/2018)

Carenza Hydrocortisone Roussel - modalità di richiesta d'importazione dall'estero (12/07/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "Hydrocortisone Roussel 10mg/cpr”, non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

2-7-2018

Carenza Haemocomplettan P - modalità di richiesta d'importazione dall'estero (02/07/2018)

Carenza Haemocomplettan P - modalità di richiesta d'importazione dall'estero (02/07/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "Haemocomplettan P (fibrinogeno da plasma umano), 1 g polvere, 1 fiala”, non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

26-6-2018

Rettifica: Carenza CINRYZE - modalità di richiesta d'Importazione dall'estero (26/06/2018)

Rettifica: Carenza CINRYZE - modalità di richiesta d'Importazione dall'estero (26/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "CINRYZE", non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

22-6-2018

Carenza fludrocortisone acetato - modalità di richiesta d'importazione dall'estero (22/06/2018)

Carenza fludrocortisone acetato - modalità di richiesta d'importazione dall'estero (22/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "fludrocortisone acetato", non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

21-6-2018

Carenza Petinimid (etosuccimide) - modalità di richiesta d'importazione dall'estero (21/06/2018)

Carenza Petinimid (etosuccimide) - modalità di richiesta d'importazione dall'estero (21/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "Petinimid (Etosuccimide)", non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

20-6-2018

Carenza IMUKIN® - modalità di richiesta d'importazione dall'estero (20/06/2018)

Carenza IMUKIN® - modalità di richiesta d'importazione dall'estero (20/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "IMUKIN®”, non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.Leggere la Determinazione AIFA in allegatoPer maggiori informazioni:contatta l' Ufficio di Qualità dei prodotti e Contrasto al Crimine Farmaceuticoseguici su facebook, twitter e you tube

Italia - AIFA - Agenzia Italiana del Farmaco

20-6-2018

Rettifica: Carenza BOOSTRIX - modalità di richiesta d'Importazione dall'estero (20/06/2018)

Rettifica: Carenza BOOSTRIX - modalità di richiesta d'Importazione dall'estero (20/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "BOOSTRIX", non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

19-6-2018

Carenza CINRYZE® - modalità di richiesta d'importazione dall'estero (19/06/2018)

Carenza CINRYZE® - modalità di richiesta d'importazione dall'estero (19/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "CINRYZE®”, non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

15-6-2018

Carenza BOOSTRIX TETRA - modalità di richiesta d'importazione dall'estero (15/06/2018)

Carenza BOOSTRIX TETRA - modalità di richiesta d'importazione dall'estero (15/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "BOOSTRIX TETRA", non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

14-6-2018

Carenza Mabcampath (alemtuzumab) - modalità di richiesta d'importazione dall'estero (14/06/2018)

Carenza Mabcampath (alemtuzumab) - modalità di richiesta d'importazione dall'estero (14/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale “Mabcampath (alemtuzumab)", non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

14-6-2018

Carenza FLUDARABINA - modalità di richiesta d'importazione dall'estero (14/06/2018)

Carenza FLUDARABINA - modalità di richiesta d'importazione dall'estero (14/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "FLUDARABINA", non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

12-6-2018

Carenza ENGERIX B® - modalità di richiesta d'importazione dall'estero (12/06/2018)

Carenza ENGERIX B® - modalità di richiesta d'importazione dall'estero (12/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "ENGERIX B®”, non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

11-6-2018

Rettifica: Carenza BOOSTRIX - modalità di richiesta d'Importazione dall'estero (11/06/2018)

Rettifica: Carenza BOOSTRIX - modalità di richiesta d'Importazione dall'estero (11/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "BOOSTRIX", non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

5-6-2018

Carenza BOOSTRIX - modalità di richiesta d'importazione dall'estero (05/06/2018)

Carenza BOOSTRIX - modalità di richiesta d'importazione dall'estero (05/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "BOOSTRIX", non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

5-6-2018

Carenza BOOSTRIX TETRA - modalità di richiesta d'importazione dall'estero (05/06/2018)

Carenza BOOSTRIX TETRA - modalità di richiesta d'importazione dall'estero (05/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "BOOSTRIX TETRA", non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

1-6-2018

Carenza Haemocomplettan P - modalità di richiesta d'importazione dall'estero (01/06/2018)

Carenza Haemocomplettan P - modalità di richiesta d'importazione dall'estero (01/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "Haemocomplettan P”, non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

30-5-2018

As part of efforts to combat opioid crisis, FDA launches innovation challenge to spur development of medical devices ‒ including digital health and diagnostics ‒ that target pain, addiction and diversion

As part of efforts to combat opioid crisis, FDA launches innovation challenge to spur development of medical devices ‒ including digital health and diagnostics ‒ that target pain, addiction and diversion

As part of efforts to combat opioid crisis, FDA launches innovation challenge to spur development of medical devices ‒ including digital health and diagnostics ‒ that target pain, addiction and diversion

FDA - U.S. Food and Drug Administration

28-5-2018

Carenza Myocet® - modalità di richiesta d'importazione dall'estero (28/05/2018)

Carenza Myocet® - modalità di richiesta d'importazione dall'estero (28/05/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "Myocet®" (lingua polacca e tedesca), non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

22-5-2018

Carenza Myocet® - modalità di richiesta d'importazione dall'estero (22/05/2018)

Carenza Myocet® - modalità di richiesta d'importazione dall'estero (22/05/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "Myocet®", non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

18-5-2018

Carenza PENTAVAC - modalità di richiesta d'importazione dall'estero (18/05/2018)

Carenza PENTAVAC - modalità di richiesta d'importazione dall'estero (18/05/2018)

L'Agenzia Italiana del Farmaco rende disponibili aggiornamenti relativi al medicinale "PENTAVAC", non reperibile sul territorio nazionale per il quale è stata autorizzata l’importazione dall’estero su richiesta dell’azienda.

Italia - AIFA - Agenzia Italiana del Farmaco

30-11-2018

.@US_FDA has selected 8 novel medical devices as participants in #FDA’s Innovation Challenge to address the #OpioidEpidemic by preventing and treating opioid use disorder. #FDAInnovationChallenge

.@US_FDA has selected 8 novel medical devices as participants in #FDA’s Innovation Challenge to address the #OpioidEpidemic by preventing and treating opioid use disorder. #FDAInnovationChallenge

. @US_FDA has selected 8 novel medical devices as participants in #FDA’s Innovation Challenge to address the #OpioidEpidemic by preventing and treating opioid use disorder. #FDAInnovationChallenge

FDA - U.S. Food and Drug Administration

12-10-2018

The 2nd week of National Cybersecurity Awareness Month is here! This  week’s theme: “Cybersecurity = A Cross-Cutting Challenge to Tackle  Together”. Learn more about #NCSAM at   https://www.dhs.gov/stopthinkconnect …. #FDA #MedicalDevicespic.twitter.com/H

The 2nd week of National Cybersecurity Awareness Month is here! This week’s theme: “Cybersecurity = A Cross-Cutting Challenge to Tackle Together”. Learn more about #NCSAM at https://www.dhs.gov/stopthinkconnect …. #FDA #MedicalDevicespic.twitter.com/H

The 2nd week of National Cybersecurity Awareness Month is here! This week’s theme: “Cybersecurity = A Cross-Cutting Challenge to Tackle Together”. Learn more about #NCSAM at https://www.dhs.gov/stopthinkconnect …. #FDA #MedicalDevices pic.twitter.com/H3rUbSyLPq

FDA - U.S. Food and Drug Administration

30-9-2018

Today is the last day to submit applications to the #FDAInnovationChallenge. Thanks to all who have applied.  Selected applications will be announced in November. For more information about the challenge, click the link:   https://go.usa.gov/xP4Nk pic.twi

Today is the last day to submit applications to the #FDAInnovationChallenge. Thanks to all who have applied. Selected applications will be announced in November. For more information about the challenge, click the link: https://go.usa.gov/xP4Nk pic.twi

Today is the last day to submit applications to the #FDAInnovationChallenge. Thanks to all who have applied. Selected applications will be announced in November. For more information about the challenge, click the link: https://go.usa.gov/xP4Nk  pic.twitter.com/pFJZ39oGJC

FDA - U.S. Food and Drug Administration

29-9-2018

Reminder: the last day to submit applications to the #FDAInnovationChallenge is tomorrow, September 30th. Click the link to find out more about the challenge and how to submit your application:  https://go.usa.gov/xP4Nk pic.twitter.com/lLYiMa0cLe

Reminder: the last day to submit applications to the #FDAInnovationChallenge is tomorrow, September 30th. Click the link to find out more about the challenge and how to submit your application: https://go.usa.gov/xP4Nk pic.twitter.com/lLYiMa0cLe

Reminder: the last day to submit applications to the #FDAInnovationChallenge is tomorrow, September 30th. Click the link to find out more about the challenge and how to submit your application: https://go.usa.gov/xP4Nk  pic.twitter.com/lLYiMa0cLe

FDA - U.S. Food and Drug Administration

24-9-2018

#FDA announces the release of the Collaborative Communities Toolkit for interested stakeholder organizations to work together on healthcare challenges. Learn about the program, download the Toolkit, and submit comments:  https://go.usa.gov/xPjKX pic.twitt

#FDA announces the release of the Collaborative Communities Toolkit for interested stakeholder organizations to work together on healthcare challenges. Learn about the program, download the Toolkit, and submit comments: https://go.usa.gov/xPjKX pic.twitt

#FDA announces the release of the Collaborative Communities Toolkit for interested stakeholder organizations to work together on healthcare challenges. Learn about the program, download the Toolkit, and submit comments: https://go.usa.gov/xPjKX  pic.twitter.com/iQsKIAAQTn

FDA - U.S. Food and Drug Administration

24-9-2018

For more information about the #FDA’s effort to address the epidemic of  #opioid addiction, click the link to find out more about the  #FDAInnovationChallenge:  https://go.usa.gov/xPja7  The last day to submit  applications is September 30th, 2018.https:/

For more information about the #FDA’s effort to address the epidemic of #opioid addiction, click the link to find out more about the #FDAInnovationChallenge: https://go.usa.gov/xPja7  The last day to submit applications is September 30th, 2018.https:/

For more information about the #FDA’s effort to address the epidemic of #opioid addiction, click the link to find out more about the #FDAInnovationChallenge: https://go.usa.gov/xPja7  The last day to submit applications is September 30th, 2018. https://twitter.com/NIDAnews/status/1032719474934382593 …

FDA - U.S. Food and Drug Administration

17-9-2018

We had lots of great questions from potential applicants during our recent webinar. Check out the recording for Q&A about the #FDAInnovationChallenge. Click the link for the webinar recording:  https://go.usa.gov/xP4N5  #FDA #MedicalDevices

We had lots of great questions from potential applicants during our recent webinar. Check out the recording for Q&A about the #FDAInnovationChallenge. Click the link for the webinar recording: https://go.usa.gov/xP4N5  #FDA #MedicalDevices

We had lots of great questions from potential applicants during our recent webinar. Check out the recording for Q&A about the #FDAInnovationChallenge. Click the link for the webinar recording: https://go.usa.gov/xP4N5  #FDA #MedicalDevices

FDA - U.S. Food and Drug Administration

17-9-2018

The #FDAInnovationChallenge to develop medical devices for #opioid addiction will provide those selected with the opportunity to work directly with the agency to accelerate the development and review of their device proposals to prevent and treat opioid u

The #FDAInnovationChallenge to develop medical devices for #opioid addiction will provide those selected with the opportunity to work directly with the agency to accelerate the development and review of their device proposals to prevent and treat opioid u

The #FDAInnovationChallenge to develop medical devices for #opioid addiction will provide those selected with the opportunity to work directly with the agency to accelerate the development and review of their device proposals to prevent and treat opioid use disorder. #FDA

FDA - U.S. Food and Drug Administration

17-9-2018

Reminder: the FDA is accepting applications through Sept. 30, 2018, for the #FDAInnovationChallenge for devices to help combat #opioid addiction.   Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the c

Reminder: the FDA is accepting applications through Sept. 30, 2018, for the #FDAInnovationChallenge for devices to help combat #opioid addiction. Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the c

Reminder: the FDA is accepting applications through Sept. 30, 2018, for the #FDAInnovationChallenge for devices to help combat #opioid addiction. Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the concept.

FDA - U.S. Food and Drug Administration

17-9-2018

 European Medicines Agency (EMA) Human Scientific Committees' Working Party with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 26-Sep-2018, To: 26-Sep-2018

European Medicines Agency (EMA) Human Scientific Committees' Working Party with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 26-Sep-2018, To: 26-Sep-2018

This Healthcare Professionals' Working Party (HCPWP) plenary meeting will include discussions on advances in clinical practice and the scientific and regulatory challenges. Members will also be invited to present how they are including regulatory sciences in fellowships and young researchers’ training. Feedback will be given from the representatives of the Scientific Committees.

Europe - EMA - European Medicines Agency

13-9-2018

 European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH), European Medicines Agency, London, UK, From: 03-Dec-2018, To: 03-Dec-2018

European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH), European Medicines Agency, London, UK, From: 03-Dec-2018, To: 03-Dec-2018

This workshop on the development of medicines for chronic non-infectious liver diseases, including primary biliary cholangitis, primary sclerosing cholangitis and nonalcoholic steatohepatitis, provides a platform for discussion on appropriate endpoints including validation of surrogate endpoints/biomarkers, suitable study populations, potentially adequate trial designs and the specific challenges with paediatric medicine development. The workshop will support the drafting of a reflection paper on regul...

Europe - EMA - European Medicines Agency

7-9-2018

 2018 Annual workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), European Medicines Agency, London, UK, From: 07-Jun-2018, To: 07-Jun-2018

2018 Annual workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), European Medicines Agency, London, UK, From: 07-Jun-2018, To: 07-Jun-2018

Enpr-EMA will hold its tenth annual workshop on 7-8 June 2018 at EMA. The workshop brings relevant stakeholders together to discuss requirements, barriers and opportunities for the conduct of high-quality clinical studies in children. The overall theme of this year’s workshop will be a ‘holistic approach to paediatric research’. Highlights of this year’s workshop include: i) short perspectives of the various stakeholders involved in paediatric research (patient/young people advisory groups, research netw...

Europe - EMA - European Medicines Agency

16-7-2018

On July 25th, the FDA will host a webinar to provide developers and interested applicants an opportunity to hear from the FDA and answer questions about the #FDAInnovationChallenge. Click the link for more information  http://go.usa.gov/xQvE9 pic.twitter.

On July 25th, the FDA will host a webinar to provide developers and interested applicants an opportunity to hear from the FDA and answer questions about the #FDAInnovationChallenge. Click the link for more information http://go.usa.gov/xQvE9 pic.twitter.

On July 25th, the FDA will host a webinar to provide developers and interested applicants an opportunity to hear from the FDA and answer questions about the #FDAInnovationChallenge. Click the link for more information http://go.usa.gov/xQvE9  pic.twitter.com/kT7EqyTPxr

FDA - U.S. Food and Drug Administration

29-6-2018

#FDAInnovationChallenge https://twitter.com/HHSGov/status/1012707386061012994 …

#FDAInnovationChallenge https://twitter.com/HHSGov/status/1012707386061012994 …

#FDAInnovationChallenge https://twitter.com/HHSGov/status/1012707386061012994 …

FDA - U.S. Food and Drug Administration

29-6-2018

#FDAInnovationChallenge https://twitter.com/SGottliebFDA/status/1012725536626536448 …

#FDAInnovationChallenge https://twitter.com/SGottliebFDA/status/1012725536626536448 …

#FDAInnovationChallenge https://twitter.com/SGottliebFDA/status/1012725536626536448 …

FDA - U.S. Food and Drug Administration

26-6-2018

Import/Export sangue e suoi prodotti: modalità di trasmissione della documentazione (26/06/2018)

Import/Export sangue e suoi prodotti: modalità di trasmissione della documentazione (26/06/2018)

L'Agenzia Italiana del Farmaco rende disponibili informazioni relative alle modalità  di deposito per l’attività di import/export di sangue e suoi prodotti, in conformità al DM 24/04/2018 “Modifiche e integrazioni al Decreto 2 dicembre 2016, concernente le disposizioni sull’importazione ed esportazione del sangue umano e dei suoi prodotti” (G.U. n.131 del 08/06/2018).

Italia - AIFA - Agenzia Italiana del Farmaco

12-6-2018

Disposizioni sull’importazione ed esportazione del sangue umano e dei suoi prodotti (12/06/2018)

Disposizioni sull’importazione ed esportazione del sangue umano e dei suoi prodotti (12/06/2018)

E’ stato pubblicato in Gazzetta Ufficiale il Decreto del Ministero della salute 24 aprile 2018 (G.U. n. 131 del 08/06/2018) recante “modifiche e integrazioni al Decreto 02/12/2016, concernente le disposizioni sull’importazione ed esportazione del sangue umano e dei suoi prodotti”. Tali disposizioni modificano le procedure amministrative relative alle modalità di importazione nel settore degli emoderivati.

Italia - AIFA - Agenzia Italiana del Farmaco

8-6-2018

#DYK Opioids are among the type of medication that are most commonly misused - https://go.usa.gov/xQ7Az  #FDAInnovationChallengepic.twitter.com/kQPmn4ezXD

#DYK Opioids are among the type of medication that are most commonly misused - https://go.usa.gov/xQ7Az  #FDAInnovationChallengepic.twitter.com/kQPmn4ezXD

#DYK Opioids are among the type of medication that are most commonly misused - https://go.usa.gov/xQ7Az  #FDAInnovationChallenge pic.twitter.com/kQPmn4ezXD

FDA - U.S. Food and Drug Administration

5-6-2018

#DYK The misuse of prescription drugs means taking a medication in a manner or dose other than prescribed; taking someone else’s prescription, even if for a legitimate medical complaint such as pain; or taking a medication to feel euphoria. #FDAInnovation

#DYK The misuse of prescription drugs means taking a medication in a manner or dose other than prescribed; taking someone else’s prescription, even if for a legitimate medical complaint such as pain; or taking a medication to feel euphoria. #FDAInnovation

#DYK The misuse of prescription drugs means taking a medication in a manner or dose other than prescribed; taking someone else’s prescription, even if for a legitimate medical complaint such as pain; or taking a medication to feel euphoria. #FDAInnovationChallenge pic.twitter.com/QI0mrJactV

FDA - U.S. Food and Drug Administration

1-6-2018

hydrocodone (Vicodin®), codeine, morphine, and many others. #DYK #FDAInnovationChallenge (2 of 2 messages)  https://go.usa.gov/xQwmW pic.twitter.com/bGlnTFOzVE

hydrocodone (Vicodin®), codeine, morphine, and many others. #DYK #FDAInnovationChallenge (2 of 2 messages) https://go.usa.gov/xQwmW pic.twitter.com/bGlnTFOzVE

hydrocodone (Vicodin®), codeine, morphine, and many others. #DYK #FDAInnovationChallenge (2 of 2 messages) https://go.usa.gov/xQwmW  pic.twitter.com/bGlnTFOzVE

FDA - U.S. Food and Drug Administration

1-6-2018

#DYK #Opioids are a type of drug that includes the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, such as oxycodone (OxyContin®) #FDAInnovationChallenge (1 of 2 messages)

#DYK #Opioids are a type of drug that includes the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, such as oxycodone (OxyContin®) #FDAInnovationChallenge (1 of 2 messages)

#DYK #Opioids are a type of drug that includes the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, such as oxycodone (OxyContin®) #FDAInnovationChallenge (1 of 2 messages)

FDA - U.S. Food and Drug Administration

30-5-2018

On July 25th, the FDA will host a webinar to provide developers and interested applicants an opportunity to hear from the FDA and answer questions about the #FDAInnovationChallenge. Click the link for more information  https://go.usa.gov/xQvE9 

On July 25th, the FDA will host a webinar to provide developers and interested applicants an opportunity to hear from the FDA and answer questions about the #FDAInnovationChallenge. Click the link for more information https://go.usa.gov/xQvE9 

On July 25th, the FDA will host a webinar to provide developers and interested applicants an opportunity to hear from the FDA and answer questions about the #FDAInnovationChallenge. Click the link for more information https://go.usa.gov/xQvE9 

FDA - U.S. Food and Drug Administration

30-5-2018

Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the concept.  https://go.usa.gov/xQvPA  #FDAInnovationChallengepic.twitter.com/wyTkvmptHJ

Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the concept. https://go.usa.gov/xQvPA  #FDAInnovationChallengepic.twitter.com/wyTkvmptHJ

Submissions will be evaluated based on the feasibility, potential public health impact and novelty of the concept. https://go.usa.gov/xQvPA  #FDAInnovationChallenge pic.twitter.com/wyTkvmptHJ

FDA - U.S. Food and Drug Administration

30-5-2018

The FDA will accept submissions from June 1, 2018, through Sept. 30, 2018, and intends to announce the selected applicants in November 2018.  #FDAInnovationChallenge

The FDA will accept submissions from June 1, 2018, through Sept. 30, 2018, and intends to announce the selected applicants in November 2018. #FDAInnovationChallenge

The FDA will accept submissions from June 1, 2018, through Sept. 30, 2018, and intends to announce the selected applicants in November 2018. #FDAInnovationChallenge

FDA - U.S. Food and Drug Administration

30-5-2018

#FDAInnovationChallenge to develop medical devices for #opioid addiction will provide those selected with the opportunity to work directly with the agency to accelerate the development & review of their device proposals to prevent and treat opioid use dis

#FDAInnovationChallenge to develop medical devices for #opioid addiction will provide those selected with the opportunity to work directly with the agency to accelerate the development & review of their device proposals to prevent and treat opioid use dis

#FDAInnovationChallenge to develop medical devices for #opioid addiction will provide those selected with the opportunity to work directly with the agency to accelerate the development & review of their device proposals to prevent and treat opioid use disorder. #FDA MedicalDevice

FDA - U.S. Food and Drug Administration

30-5-2018

Please click the link for more information on the #FDAInnovationChallenge  https://go.usa.gov/xQvPA 

Please click the link for more information on the #FDAInnovationChallenge https://go.usa.gov/xQvPA 

Please click the link for more information on the #FDAInnovationChallenge https://go.usa.gov/xQvPA 

FDA - U.S. Food and Drug Administration

30-5-2018

As part of FDA’s ongoing effort to address the epidemic of #opioid addiction, the agency has announced an innovation challenge to spur development of medical devices, including digital health and diagnostic devices, to help combat opioid addiction. #FDAIn

As part of FDA’s ongoing effort to address the epidemic of #opioid addiction, the agency has announced an innovation challenge to spur development of medical devices, including digital health and diagnostic devices, to help combat opioid addiction. #FDAIn

As part of FDA’s ongoing effort to address the epidemic of #opioid addiction, the agency has announced an innovation challenge to spur development of medical devices, including digital health and diagnostic devices, to help combat opioid addiction. #FDAInnovationChallenge pic.twitter.com/W21hFOinRg

FDA - U.S. Food and Drug Administration